drug discovery

We caught up with Michael O’Rourke, Chief Executive Officer at Re-Vana Therapeutics, which is developing sustained release biologics and small molecule drugs...

We caught up with Dave Llewellyn, CEO of DJS Antibodies, as part of ‘Product | People | Potential’. DJS Antibodies has developed HEPTAD, a novel...

Our chat with Dr Arron Tolley, CEO at Aptamer Group. Aptamer Group utilises high-throughput, in-vitro techniques to select aptamers that are engineered to bi...